Time in therapeutic range: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Factors Affecting Time in Therapeutic Range== | ==Factors Affecting Time in Therapeutic Range== | ||
Cross Trial Comparisons of TTR are hampered by variations in: | |||
• CHADS Score: Higher the CHADS score, lower the TTR. Sicker patients may have reduced access to frequent testing. | |||
• Age: Older patients may have reduced access to frequent testing | |||
• CHF: Varying drug clearance and distribution (CHF: 63% in ROCKET, 32% RELY, 35% ARISTOTLE) | |||
• Country: Highest in Scandanavia, lowest in developing countries | |||
• What is the TTR in ROCKET AF in those countries who conducted RE-LY and vice versa (adjusting for the number of sites in each country)? | |||
• Should trials only be conducted in countries with a high TTR or should sponsors conduct real world trials throughout the world? | |||
Revision as of 12:41, 8 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and Keywords: TTR
Overview
Factors Affecting Time in Therapeutic Range
Cross Trial Comparisons of TTR are hampered by variations in:
• CHADS Score: Higher the CHADS score, lower the TTR. Sicker patients may have reduced access to frequent testing.
• Age: Older patients may have reduced access to frequent testing
• CHF: Varying drug clearance and distribution (CHF: 63% in ROCKET, 32% RELY, 35% ARISTOTLE)
• Country: Highest in Scandanavia, lowest in developing countries
• What is the TTR in ROCKET AF in those countries who conducted RE-LY and vice versa (adjusting for the number of sites in each country)?
• Should trials only be conducted in countries with a high TTR or should sponsors conduct real world trials throughout the world?